201 Elliott Avenue West
333 articles with Omeros Corporation
Omeros Corporation Streamlines Path to Biologics License Application for OMS721 in HSCT-TMA Following Meeting with FDA
Patient Data from Existing Single-Arm Study Will Form the Basis for BLA; No Historical Control Required
Former Lilly Biotechnology and Immunology Senior Vice President Drawn by Omeros’ Complement Franchise and Novel-Product Pipeline
Additional Positive Data Reported from Second Cohort in Phase 2 Trial
Broadening OMIDRIA Coverage from Payers and Increasing Funding for OMS721 Commercial Preparations
Omeros Establishes Independent Academic Leadership Committee for its OMS721 Phase 3 Clinical Program in IgA Nephropathy
Committee is Comprised of World Leaders in IgA Nephropathy and Renal Clinical Research
Newly Established Center Will Focus on Complement and Inflammation
Omeros Announces Clinical Strategy to Accelerate Pediatric Development of OMS721 for the Treatment of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (HSCT-TMA)
EMA Confirmed OMS721 Eligibility for European Centralized Marketing Authorization Application Review
Hires Commercial and CMC Heads from Celgene
Omeros Corporation today announced its intention to offer, subject to market and other conditions, $210 million aggregate principal amount of its Convertible Senior Notes due 2023 (the "Notes") in a private offering (the "Offering") to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933
Conference Call Friday, November 9th at 8:30 a.m. ET
Omeros Corporation today announced that the company will issue its third quarter 2018 financial results for the period ended September 30, 2018, on Friday, November 9, 2018, before the market opens. Omeros management will host a conference call and webcast that day at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) to discuss the financial results.
FDA Grants Orphan Drug Designation to Omeros’ OMS721 for Treatment of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy
OMS721 now with orphan designation covering both prevention and treatment of HSCT-TMA in U.S. and in Europe
CMS’ Separate Payment for Cataract Surgery Drug Resumes Today
Job hunting can be a challenging time for people. Finding open positions that fit your skill set and then competing with other highly-qualified people can be bruising, especially if you’re already a bit damaged from a recent layoff.
European Commission Designates OMS721 as an Orphan Medicinal Product for Treatment in Hematopoietic Stem Cell Transplantation
Omeros Corporation (Nasdaq: OMER) today announced that the European Commission (EC) has adopted a decision designating OMS721 as an Orphan Medicinal Product in the European Union (EU) for treatment in hematopoietic stem cell transplantation (HSCT).
Omeros Corporation announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the 2018 Wedbush PacGrow Healthcare Conference in New York next week. The presentation is scheduled for Tuesday, August 14, 2018 at 2:30 p.m. EDT.
Conference Call Today at 4:30 p.m. ET
Omeros Corporation announced that the company will issue its second quarter 2018 financial results for the period ended June 30, 2018, on Thursday, August 9, 2018, after the market closes.
Company Expands Leadership to Keep Pace with Advancing Pivotal Clinical Programs
Sandoz Amends ANDA to Not Seek Approval for Generic Version of OMIDRIA Until Patents for Omeros’ Drug Expire
With Voluntary Dismissal of Infringement Suit Against Sandoz, Omeros Wraps Up All Pending ANDA Litigation